Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 7/20 | 0.52 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.45 |
| ▸ | FNTB | P49356 | 1/20 | 0.45 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.45 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5549701 | 0.91 | XDH (0.42) | XDHGSK3AGSK3BFNTAFNTB | |
| SCHEMBL14584981 | 0.91 | XDH (0.42) | XDHGSK3AGSK3BCCNT1CCNA2 | |
| SCHEMBL5550074 | 0.89 | CSF1R (0.43) | XDHIKBKETBK1 | |
| SCHEMBL14584976 | 0.89 | XDH (0.50) | XDHGSK3AGSK3BCCNT1CCNA2 | |
| SCHEMBL14402358 | 0.88 | XDH (0.49) | XDHGSK3AGSK3BCCNT1CCNA2 | |
| SCHEMBL5544745 | 0.87 | XDH (0.49) | XDHFNTAFNTBPGGT1B | |
| SCHEMBL13887205 | 0.87 | XDH (0.48) | XDHGSK3AGSK3BCCNT1CCNA2 | |
| SCHEMBL14584977 | 0.87 | RXFP1 (0.44) | XDHCCNA2CDK2CCNA1 | |
| SCHEMBL5546960 | 0.86 | PKMYT1 (0.44) | GSK3AGSK3BTBK1AURKA | |
| SCHEMBL5550328 | 0.85 | GSK3A (0.41) | XDHGSK3AGSK3BIKBKETBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1442019-B1 | AMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3-BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-10 | — | — | EP | claimed |
| US-7183288-B2 | Amide derivatives as glycogen synthase kinase 3-β inhibitors | FREYNE EDDY JEAN EDGARD | 2007-02-27 | — | — | US | claimed |
| US-20050176713-A1 | Amide derivatives as glycogen synthase kinase 3-beta inhibitors | FREYNE EDDY JEAN E (BE) | 2005-08-11 | — | — | US | claimed |
| EP-1442019-A1 | AMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3-BETA INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-04 | — | — | EP | claimed |
| WO-2003037869-A1 | AMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3-BETA INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-05-08 | — | — | WO | claimed |
| EP-1442019-B1 | AMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3-BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-10 | — | — | EP | disclosed |
| EP-1442019-B1 | AMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3-BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-10 | — | — | EP | disclosed |
| US-7183288-B2 | Amide derivatives as glycogen synthase kinase 3-β inhibitors | FREYNE EDDY JEAN EDGARD | 2007-02-27 | — | — | US | disclosed |
| US-7183288-B2 | Amide derivatives as glycogen synthase kinase 3-β inhibitors | FREYNE EDDY JEAN EDGARD | 2007-02-27 | — | — | US | disclosed |
| US-7183288-B2 | Amide derivatives as glycogen synthase kinase 3-β inhibitors | FREYNE EDDY JEAN EDGARD | 2007-02-27 | — | — | US | disclosed |
| US-20050176713-A1 | Amide derivatives as glycogen synthase kinase 3-beta inhibitors | FREYNE EDDY JEAN E (BE) | 2005-08-11 | — | — | US | disclosed |
| EP-1442019-A1 | AMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3-BETA INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003037869-A1 | AMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3-BETA INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176713-A1 | Amide derivatives as glycogen synthase kinase 3-beta inhibitors | GSK3B, GSK3A, PHKG1 | XDH 1032/4885GSK3A 2/4885GSK3B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.